Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced  positive results from its Phase 3 HYPERION trial of WINREVAIR in adults recently diagnosed with pulmonary arterial hypertension. The trial included patients classified as functional class 2 or 3 and at intermediate or high risk of disease progression. Management noted that the drug reduced the risk of clinical worsening events by 76% compared to placebo. Moreover ...